BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

412 related articles for article (PubMed ID: 30755442)

  • 41. Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical models.
    Ng SY; Yoshida N; Christie AL; Ghandi M; Dharia NV; Dempster J; Murakami M; Shigemori K; Morrow SN; Van Scoyk A; Cordero NA; Stevenson KE; Puligandla M; Haas B; Lo C; Meyers R; Gao G; Cherniack A; Louissaint A; Nardi V; Thorner AR; Long H; Qiu X; Morgan EA; Dorfman DM; Fiore D; Jang J; Epstein AL; Dogan A; Zhang Y; Horwitz SM; Jacobsen ED; Santiago S; Ren JG; Guerlavais V; Annis DA; Aivado M; Saleh MN; Mehta A; Tsherniak A; Root D; Vazquez F; Hahn WC; Inghirami G; Aster JC; Weinstock DM; Koch R
    Nat Commun; 2018 May; 9(1):2024. PubMed ID: 29789628
    [TBL] [Abstract][Full Text] [Related]  

  • 42. SAR405838: an optimized inhibitor of MDM2-p53 interaction that induces complete and durable tumor regression.
    Wang S; Sun W; Zhao Y; McEachern D; Meaux I; Barrière C; Stuckey JA; Meagher JL; Bai L; Liu L; Hoffman-Luca CG; Lu J; Shangary S; Yu S; Bernard D; Aguilar A; Dos-Santos O; Besret L; Guerif S; Pannier P; Gorge-Bernat D; Debussche L
    Cancer Res; 2014 Oct; 74(20):5855-65. PubMed ID: 25145672
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficient p53 activation and apoptosis by simultaneous disruption of binding to MDM2 and MDMX.
    Hu B; Gilkes DM; Chen J
    Cancer Res; 2007 Sep; 67(18):8810-7. PubMed ID: 17875722
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The long and the short of it: the MDM4 tail so far.
    Haupt S; Mejía-Hernández JO; Vijayakumaran R; Keam SP; Haupt Y
    J Mol Cell Biol; 2019 Mar; 11(3):231-244. PubMed ID: 30689920
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Synergistic roles of Mdm2 and Mdm4 for p53 inhibition in central nervous system development.
    Xiong S; Van Pelt CS; Elizondo-Fraire AC; Liu G; Lozano G
    Proc Natl Acad Sci U S A; 2006 Feb; 103(9):3226-31. PubMed ID: 16492743
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Rare MDM4 gene amplification in colorectal cancer: The principle of a mutually exclusive relationship between MDM alteration and TP53 inactivation is not applicable.
    Suda T; Yoshihara M; Nakamura Y; Sekiguchi H; Godai TI; Sugano N; Tsuchida K; Shiozawa M; Sakuma Y; Tsuchiya E; Kameda Y; Akaike M; Matsukuma S; Miyagi Y
    Oncol Rep; 2011 Jul; 26(1):49-54. PubMed ID: 21503588
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effect of telomerase inhibition on preclinical models of malignant rhabdoid tumor.
    Hu Y; Bobb D; Lu Y; He J; Dome JS
    Cancer Genet; 2014 Sep; 207(9):403-11. PubMed ID: 25441685
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Context-dependent roles of MDMX (MDM4) and MDM2 in breast cancer proliferation and circulating tumor cells.
    Gao C; Xiao G; Piersigilli A; Gou J; Ogunwobi O; Bargonetti J
    Breast Cancer Res; 2019 Jan; 21(1):5. PubMed ID: 30642351
    [TBL] [Abstract][Full Text] [Related]  

  • 49. XI-011 enhances cisplatin-induced apoptosis by functional restoration of p53 in head and neck cancer.
    Roh JL; Park JY; Kim EH
    Apoptosis; 2014 Nov; 19(11):1594-602. PubMed ID: 25113507
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Insulin-like growth factor 2 axis supports the serum-independent growth of malignant rhabdoid tumor and is activated by microenvironment stress.
    Li T; Wang J; Liu P; Chi J; Yan H; Lei L; Li Z; Yang B; Wang X
    Oncotarget; 2017 Jul; 8(29):47269-47283. PubMed ID: 28521298
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Human glioblastoma multiforme: p53 reactivation by a novel MDM2 inhibitor.
    Costa B; Bendinelli S; Gabelloni P; Da Pozzo E; Daniele S; Scatena F; Vanacore R; Campiglia P; Bertamino A; Gomez-Monterrey I; Sorriento D; Del Giudice C; Iaccarino G; Novellino E; Martini C
    PLoS One; 2013; 8(8):e72281. PubMed ID: 23977270
    [TBL] [Abstract][Full Text] [Related]  

  • 52. TP53/miR-129/MDM2/4/TP53 feedback loop modulates cell proliferation and apoptosis in retinoblastoma.
    Yao X; Shen H; Peng Q; Yu J
    Cell Cycle; 2021; 20(5-6):603-615. PubMed ID: 33678118
    [TBL] [Abstract][Full Text] [Related]  

  • 53. MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer models.
    Tovar C; Graves B; Packman K; Filipovic Z; Higgins B; Xia M; Tardell C; Garrido R; Lee E; Kolinsky K; To KH; Linn M; Podlaski F; Wovkulich P; Vu B; Vassilev LT
    Cancer Res; 2013 Apr; 73(8):2587-97. PubMed ID: 23400593
    [TBL] [Abstract][Full Text] [Related]  

  • 54. p53 as a target for the treatment of cancer.
    Duffy MJ; Synnott NC; McGowan PM; Crown J; O'Connor D; Gallagher WM
    Cancer Treat Rev; 2014 Dec; 40(10):1153-60. PubMed ID: 25455730
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy.
    Tovar C; Rosinski J; Filipovic Z; Higgins B; Kolinsky K; Hilton H; Zhao X; Vu BT; Qing W; Packman K; Myklebost O; Heimbrook DC; Vassilev LT
    Proc Natl Acad Sci U S A; 2006 Feb; 103(6):1888-93. PubMed ID: 16443686
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Downregulation of Mdm2 and Mdm4 enhances viral gene expression during adenovirus infection.
    Yang H; Zheng Z; Zhao LY; Li Q; Liao D
    Cell Cycle; 2012 Feb; 11(3):582-93. PubMed ID: 22262167
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Novel MDM2 inhibitor SAR405838 (MI-773) induces p53-mediated apoptosis in neuroblastoma.
    Lu J; Guan S; Zhao Y; Yu Y; Wang Y; Shi Y; Mao X; Yang KL; Sun W; Xu X; Yi JS; Yang T; Yang J; Nuchtern JG
    Oncotarget; 2016 Dec; 7(50):82757-82769. PubMed ID: 27764791
    [TBL] [Abstract][Full Text] [Related]  

  • 58. FAM193A is a positive regulator of p53 activity.
    Szwarc MM; Guarnieri AL; Joshi M; Duc HN; Laird MC; Pandey A; Khanal S; Dohm E; Bui AK; Sullivan KD; Galbraith MD; Andrysik Z; Espinosa JM
    Cell Rep; 2023 Mar; 42(3):112230. PubMed ID: 36897777
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Discovery of JN122, a Spiroindoline-Containing Molecule that Inhibits MDM2/p53 Protein-Protein Interaction and Exerts Robust In Vivo Antitumor Efficacy.
    Cheng J; Yan Z; Jiang K; Liu C; Xu D; Lyu X; Hu X; Zhang S; Zhou Y; Li J; Zhao Y
    J Med Chem; 2023 Dec; 66(24):16991-17025. PubMed ID: 38062557
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Targeting dependency on a paralog pair of CBP/p300 against de-repression of KREMEN2 in SMARCB1-deficient cancers.
    Sasaki M; Kato D; Murakami K; Yoshida H; Takase S; Otsubo T; Ogiwara H
    Nat Commun; 2024 Jun; 15(1):4770. PubMed ID: 38839769
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.